1) Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With
Inoperable Liver Cancer (SORAMIC): http://clinicaltrials.gov/ct2/show/NCT01126645.
2) Llovet J, Ricci S, Mazzaferro V et al para el grupo de estudio de investigadores
SHARP. Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine
2008; 359: 378-390.
3) Ricke J, Bulla K, Kolligs F et al. Safety and toxicity of radioembolization plus
Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre
trial SORAMIC, Liver International 2015 Feb;35(2):620--626.
4) Ferlay J, Soerjomataram I, Ervik M et al. Globocan 2012. v1.0, Cancer Incidence and
Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International
Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed
on 4/March/2016. [Age-standardised rates]
5) European Association for the Study of the Liver, European Organisation for Research
and Treatment of Cancer. EASL-EORTC clinical practice guidelines: Management of
hepatocellular carcinoma. Journal of Hepatology 2012; 56: 908-943.
Photo:
http://photos.prnewswire.com/prnh/20160304/340646LOGO
CONTACTO: Para más información, contacte con: Gudrun Omarsdottir,Responsable del Proyecto SORAMIC, Universidad Otto von Guericke deMagdeburgo / Facultad de Medicina, Leipziger Str. 44, 39120 Magdeburgo,Alemania, Teléfono: +49-(0)391-67-15591, Fax: +49-(0)391-67-13383, E-mail:gudrun.omarsdottir@med.ovgu.de
